Valuation: Vaccinex, Inc.

Market Cap 2.88M 2.5M 2.33M 2.14M 4.05M 274M 4.09M 27.48M 10.74M 137M 10.81M 10.57M 454M P/E 2023
-0.21x
P/E 2024 -0.11x
Enterprise Value 1.8M 1.56M 1.45M 1.34M 2.53M 171M 2.55M 17.15M 6.7M 85.43M 6.75M 6.6M 283M EV / Sales 2023
12.3x
EV / Sales 2024 2.56x
Free-Float
88.59%
Yield 2023 *
-
Yield 2024 -
1 day+29.45%
1 week-15.25%
Current month+18.25%
1 month-1.96%
6 months-17.36%
Current year-7.02%
1 week 0.85
Extreme 0.845698
1.18
1 month 0.85
Extreme 0.845698
1.29
Current year 0.34
Extreme 0.34
1.5
1 year 0.31
Extreme 0.31
1.5
3 years 0.25
Extreme 0.2521
58.17
5 years 0.25
Extreme 0.2521
546
10 years 0.25
Extreme 0.2521
2,568.3
Manager TitleAgeSince
Chief Executive Officer 80 2001-03-31
Director of Finance/CFO 54 2024-03-13
Chief Operating Officer 54 2021-05-10
Director TitleAgeSince
Director/Board Member 80 2001-03-31
Chairman 79 2001-03-31
Director/Board Member 69 2015-01-31
Date Insider Type Main position Quantity % Market Cap.
11/14/24 Other

Founder

46,153 1.6512%
11/14/24 Other

Chairman

0 0%
11/14/24
Friedberg Mercantile Group Ltd. /Friedberg Family/
OtherCompany 615,402 22.0164%
Change 5-day change 1-year change 3-year change Capi.($)
+29.45%-15.25%+26.59%-98.38% 3.08M
+10.00%+13.39%+51.99%+83.45% 56.7B
+0.80%-7.82%+24.61%+60.00% 51.97B
-0.98%+0.29%-14.90%-14.35% 23.33B
+0.30%-5.71%-9.15%+345.82% 21.34B
+1.73%-1.57%+35.40%-28.62% 17.44B
+4.29%+1.67%+201.24%+344.48% 14.77B
+1.71%+0.34%+50.30%+169.75% 13.84B
+4.16%+4.75%+462.40%+177.20% 12.12B
+5.30%-7.93%+67.97%+162.62% 11.14B
Average +5.43%-0.56%+89.65%+120.20% 22.26B
Weighted average by Cap. +3.54%+0.44%+64.36%+115.84%

Financials

2023 2024
Net sales 570K 495K 461K 424K 802K 54.22M 811K 5.44M 2.13M 27.1M 2.14M 2.09M 89.81M 601K 522K 487K 447K 845K 57.17M 855K 5.74M 2.24M 28.58M 2.26M 2.21M 94.69M
Net income -20.25M -17.58M -16.39M -15.06M -28.48M -1.93B -28.8M -193M -75.56M -963M -76.05M -74.38M -3.19B -18.63M -16.18M -15.09M -13.86M -26.21M -1.77B -26.5M -178M -69.53M -886M -69.98M -68.44M -2.94B
Net Debt -1.29M -1.12M -1.04M -958K -1.81M -123M -1.83M -12.29M -4.81M -61.24M -4.84M -4.73M -203M -1.08M -940K -876K -805K -1.52M -103M -1.54M -10.33M -4.04M -51.45M -4.06M -3.97M -170M
Logo Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including neuroinflammatory and neurodegenerative diseases and cancer. It also discovered VX5 using its ActivMAb platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of autoimmune disorders.
Employees
25
Date Price Change Volume
26-08-04 US$1.120 -2.61% 152
26-08-03 US$1.150 +35.98% 2,001
  1. Stock Market
  2. Stocks
  3. VCNX Stock